RandyW Posted August 12, 2006 Share Posted August 12, 2006 LUNG CANCER VACCINES Lung cancer affects more than 1.2 million patients a year, with around 500,000 in the US, Europe and Japan. Non-small cell lung cancer is one of the leading causes of death, resulting in the worst survival rates for all cancers and killing more patients than breast, colon and prostate cancer together. Answering key business questions -Merck and GSK are fighting for the lion's share of the as yet unexploited multi billion US$ cervical cancer vaccine market. What differentiates the two products and how might this affect their sales? -Dendreon has an open market with its prostate cancer vaccine Provenge. But does it have the sales experience and marketing muscle to achieve sales estimated at US$799 million in 2011? -Will GSK/Avant Immunotherapuetics' monovalent vaccine derived from human rotavirus strain Rotarix 2-dose regimen see off competition from Merck's Rotateq in the US$2 billion rotavirus market? -In a sector free of competition, Merck faces considerable marketing challenges for its Herpes Zoster vaccine Zostamax. What are they? This chapter covers: - Current Market Size - Addressable Patient Population - Current Treatments - Sales Drivers - Sales Breakers - Future Treatments - Early Stage - Market Dynamics - Winners and Losers - Key launches to 2011 - Competitor Ratio Analysis - Products - Competitor Ratio Analysis - Companies For more information visit http://www.researchandmarkets.com/reports/c40622 Quote Link to comment Share on other sites More sharing options...
Recommended Posts
Join the conversation
You can post now and register later. If you have an account, sign in now to post with your account.